Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).

Hagino H, Tanaka S, Kuroda T, Mori S, Soen S

Journal of bone and mineral metabolism16 May 2024Cited by 1 (Europe PMC)

PMID38755328PMCIDPMC11147828DOI10.1007/s00774-024-01515-5PepBankPUB-38755328

Summary

IntroductionThe purpose of this study was to evaluate whether bone mineral density (BMD) ≥ -2.5 SD could be used as the treat-to-target (T2T) goal when treating osteoporosis with teriparatide (TPTD) and alendronate (ALN), and to investigate the relationship with incident vertebral fracture by re-analyzing data from a randomized, controlled trial (JOINT-05) involving postmenopausal Japanese women at high fracture risk.Materials and methodsParticipants received sequential therapy with once-weekly TPTD for 72 weeks, followed by ALN for 48 weeks (TPTD-ALN group) or ALN monotherapy for 120 weeks (ALN group). BMDs were measured at the lumbar spine (L2-4), total hip, and femoral neck at 0, 24, 48, 72, and 120 weeks by dual-energy X-ray absorptiometry. The T2T goal was BMD ≥ -2.5 SD, and the endpoint was the proportion of participants with baseline BMD < -2.5 SD in three measurement sites achieving BMD ≥ -2.5 SD.ResultsA total of 559 participants were selected. BMD ≥ -2.5 SD at 120 weeks in the L2-4, total hip, and femoral neck sites was achieved in 20.5%, 23.1%, and 5.9%, respectively, in the TPTD-ALN group and 22.2%, 11.7%, and 7.3%, respectively, in the ALN group. Incident vertebral fractures occurred in areas of both lower and high BMD.ConclusionDuring the 1.5-year treatment period, more than 20% of participants achieved BMD ≥ -2.5 SD as a T2T goal at L2-4. Since the achievement level differed depending on the BMD measurement site, the appropriate site should be selected according to the baseline BMD level.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In Japanese women with osteoporosis, lumbar spine BMD target attainment was 20.5% with sequential teriparatide-alendronate versus 22.2% with alendronate at 120 weeks.
In plain wordsIn women with osteoporosis, spine bone density target attainment was 20.5% with sequential teriparatide-alendronate versus 22.2% with alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLumbar spine BMD target attainment
Study
n: not reported in source
Comparator
Alendronate monotherapy
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD ≥ -2.5 SD attainment
20.5%
L2-4, TPTD-ALN group at 120 weeks
BMD ≥ -2.5 SD attainment
22.2%
L2-4, ALN group at 120 weeks
Source sentences
Summary
BMD ≥ -2.5 SD at 120 weeks in the L2-4, total hip, and femoral neck sites was achieved in 20.5%, 23.1%, and 5.9%, respectively, in the TPTD-ALN group and 22.2%, 11.7%, and 7.3%, respectively, in the ALN group.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants received sequential therapy with once-weekly TPTD for 72 weeks, followed by ALN for 48 weeks (TPTD-ALN group) or ALN monotherapy for 120 weeks (ALN group).
Summary · context
The T2T goal was BMD ≥ -2.5 SD, and the endpoint was the proportion of participants with baseline BMD < -2.5 SD in three measurement sites achieving BMD ≥ -2.5 SD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3875532801
02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In Japanese women with osteoporosis, total hip BMD target attainment was 23.1% with sequential teriparatide-alendronate versus 11.7% with alendronate at 120 weeks.
In plain wordsIn women with osteoporosis, total hip bone density target attainment was 23.1% with sequential teriparatide-alendronate versus 11.7% with alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD target attainment
Study
n: not reported in source
Comparator
Alendronate monotherapy
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD ≥ -2.5 SD attainment
23.1%
total hip, TPTD-ALN group at 120 weeks
BMD ≥ -2.5 SD attainment
11.7%
total hip, ALN group at 120 weeks
Source sentences
Summary
BMD ≥ -2.5 SD at 120 weeks in the L2-4, total hip, and femoral neck sites was achieved in 20.5%, 23.1%, and 5.9%, respectively, in the TPTD-ALN group and 22.2%, 11.7%, and 7.3%, respectively, in the ALN group.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants received sequential therapy with once-weekly TPTD for 72 weeks, followed by ALN for 48 weeks (TPTD-ALN group) or ALN monotherapy for 120 weeks (ALN group).
Summary · context
The T2T goal was BMD ≥ -2.5 SD, and the endpoint was the proportion of participants with baseline BMD < -2.5 SD in three measurement sites achieving BMD ≥ -2.5 SD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3875532802
03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In Japanese women with osteoporosis, femoral neck BMD target attainment was 5.9% with sequential teriparatide-alendronate versus 7.3% with alendronate at 120 weeks.
In plain wordsIn women with osteoporosis, femoral neck bone density target attainment was 5.9% with sequential teriparatide-alendronate versus 7.3% with alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseFemoral neck BMD target attainment
Study
n: not reported in source
Comparator
Alendronate monotherapy
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD ≥ -2.5 SD attainment
5.9%
femoral neck, TPTD-ALN group at 120 weeks
BMD ≥ -2.5 SD attainment
7.3%
femoral neck, ALN group at 120 weeks
Source sentences
Summary
BMD ≥ -2.5 SD at 120 weeks in the L2-4, total hip, and femoral neck sites was achieved in 20.5%, 23.1%, and 5.9%, respectively, in the TPTD-ALN group and 22.2%, 11.7%, and 7.3%, respectively, in the ALN group.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants received sequential therapy with once-weekly TPTD for 72 weeks, followed by ALN for 48 weeks (TPTD-ALN group) or ALN monotherapy for 120 weeks (ALN group).
Summary · context
The T2T goal was BMD ≥ -2.5 SD, and the endpoint was the proportion of participants with baseline BMD < -2.5 SD in three measurement sites achieving BMD ≥ -2.5 SD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3875532803
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In the osteoporosis trial of sequential teriparatide-alendronate versus alendronate, vertebral fractures occurred in areas of both lower and high BMD.
In plain wordsIn the osteoporosis trial of sequential teriparatide-alendronate versus alendronate, vertebral fractures occurred with both lower and high bone density.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableVertebral fracture occurrence across BMD levels
Study
n = 559
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Incident vertebral fractures occurred in areas of both lower and high BMD.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants received sequential therapy with once-weekly TPTD for 72 weeks, followed by ALN for 48 weeks (TPTD-ALN group) or ALN monotherapy for 120 weeks (ALN group).
Summary · context
The T2T goal was BMD ≥ -2.5 SD, and the endpoint was the proportion of participants with baseline BMD < -2.5 SD in three measurement sites achieving BMD ≥ -2.5 SD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3875532804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.